Skip to main content
Top
Published in: Clinical and Experimental Nephrology 3/2016

Open Access 01-06-2016 | Guideline

Evidence-based clinical practice guidelines for nephrotic syndrome 2014

Authors: Shinichi Nishi, Yoshifumi Ubara, Yasunori Utsunomiya, Koichi Okada, Yoko Obata, Hiroyasu Kai, Hideyasu Kiyomoto, Shin Goto, Tsuneo Konta, Yoshie Sasatomi, Yoshinobu Sato, Tomoya Nishino, Kazuhiko Tsuruya, Kengo Furuichi, Junichi Hoshino, Yasuhiro Watanabe, Kenjiro Kimura, Seiichi Matsuo

Published in: Clinical and Experimental Nephrology | Issue 3/2016

Login to get access

Excerpt

In Japan, original researches on nephrotic syndrome (NS) were initially performed by the Ministry of Health, Labour and Welfare (MHLW) NS research group. The first definition of NS was reported by the MHLW NS research group in 1973. Subsequently, the criteria for treatment effects were documented in 1974. Based on the continued clinical researches and social actions by the HLWM NS research group, the definition of refractory NS was determined in 1999. NS already treated with various agents, including steroids, that does not reach complete or incomplete remission within 6 months after the initiation of treatment is known as refractory NS. …
Metadata
Title
Evidence-based clinical practice guidelines for nephrotic syndrome 2014
Authors
Shinichi Nishi
Yoshifumi Ubara
Yasunori Utsunomiya
Koichi Okada
Yoko Obata
Hiroyasu Kai
Hideyasu Kiyomoto
Shin Goto
Tsuneo Konta
Yoshie Sasatomi
Yoshinobu Sato
Tomoya Nishino
Kazuhiko Tsuruya
Kengo Furuichi
Junichi Hoshino
Yasuhiro Watanabe
Kenjiro Kimura
Seiichi Matsuo
Publication date
01-06-2016
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2016
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-015-1216-x

Other articles of this Issue 3/2016

Clinical and Experimental Nephrology 3/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.